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Dysregulation of the intestinal epithelial barrier in genetically
susceptible individuals may lead to both intestinal and extra-
intestinal autoimmune disorders. There is emerging literature on
the role of microbiota changes in the pathogenesis of systemic
rheumatic diseases such as rheumatoid arthritis, spondyloar-
thropathies, and connective tissue diseases. Although the role of
the gastrointestinal tract in the pathogenesis of spondyloar-
tropathies is well deﬁned and many studies underline the impor-
tance of gastrointestinal inﬂammation in modulating local and
systemic inﬂammation, the data are inconclusive regarding the
effect of dysbiosis on rheumatoid arthritis and connective tissue
diseases. This review aims to summarize current data on the role
of the gastrointestinal involvement and intestinal microbiota in
the pathogenesis of systemic rheumatic disease.
© 2016 Elsevier Ltd. All rights reserved.Introduction
The gastrointestinal tract regulates the trafﬁcking of macromolecules between the environment
and the host through an epithelial barrier mechanism [1]. The intestinal epithelial barrier, together
with the gut-associated lymphoid tissue and neuroendocrine network, plays a fundamental role in
controlling the equilibrium between tolerance and immunity to non-self-antigens [1]. Dysregulation of
this organ in genetically susceptible individuals may lead to both intestinal and extraintestinalax: þ39 0916552189.
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represent the so-called microbiota [2]. These microorganisms are not mere bystanders because they
play metabolic, trophic, and protective roles and participate in normal human development and ho-
meostasis [2]. The perturbation of this interaction results in dysbiosis that in turn may inﬂuence the
susceptibility of the host to many immune-mediated diseases. There is emerging literature on the role
of microbiota changes in the pathogenesis of systemic autoimmune disease such as type 1 diabetes,
celiac disease, ankylosing spondylitis (AS), and rheumatoid arthritis (RA). This review aims to sum-
marize the current data on the role of the gastrointestinal involvement and intestinal microbiota in the
pathogenesis of systemic rheumatic disease.
Rheumatoid arthritis
RA is a chronic autoimmune inﬂammatory disorder affecting 0.5e1% of the population [3]. Although
the cause of RA remains elusive, it has been demonstrated that in genetically predisposed subjects
carrying the (Human Leukocyte Antigen) HLAeDRB1*04 cluster, environmental factors such as the oral
and gut microbiota may lead to the abnormal activation of the innate and adaptive immunity, which
involve cellular and humoral immune responses [4]. This activation leads to the formation of auto-
antibodies [rheumatoid factors (RF) and antibodies against citrullinated peptides/proteins (ACPA)] and
invasion of T cells and B cells into the synovium [4] (Fig. 1). Loss of intestinal integrity and increased
intestinal permeability have been demonstrated in RA patients, particularly those receiving non steroid
anti-inﬂammatory drugs (NSAIDs) and those with active joint disease [5e7]. Alteration of intestinal
permeability may facilitate antigenic absorption and contribute to the persistence of the disease;
however, more studies are required to further clarify this speciﬁc issue.
Gastrointestinal microbiota in rheumatoid arthritis patients
Many studies have asserted the role of gastrointestinal microbiota in the pathogenesis of RA. This is
suggested by the evidence that the oral bacteria Porphyromonas gingivalis (PG) is capable of inducing
the local production of citrullinated protein [8]. PG is a leading pathogen of chronic periodontitis [9]
and produces a unique bacterial enzyme, PG peptidyl-arginine deiminase (PPAD), which has the
ability to convert arginine residues in proteins to citrulline [8]. Because protein citrullination alters the
protein structure, PPAD may be involved in the alteration of the host signaling network and immune
evasion (Fig. 1).
Unlike in the case of the oral microbiome, conﬂicting data emerge from the studies of the intestinal
microbiome in animal models of RA and in humans. Data from murine studies support the role of
microbiota in inﬂuencing arthritis susceptibility. Liu X et al. [10] performed 16S rRNA sequencing to
characterize the gutmicrobiota of DBA1mice that did or did not develop collagen-induced arthritis and
demonstrated marked and signiﬁcant divergence in the distribution of microbiota after arthritis in-
duction. Mice susceptible to collagen-induced arthritis (CIA) showed enriched operational taxonomic
units (OTUs) afﬁliated with the genus Lactobacillus prior to arthritis onset. With disease development,
the abundance of OTUs afﬁliated with the families Bacteroidaceae, Lachnospiraceae, and S24-7 signif-
icantly increased in CIA-susceptible mice. Notably, germ-free mice conventionalized with the micro-
biota from CIA-susceptible mice showed a higher frequency of arthritis induction than those
conventionalized with the microbiota from CIA-resistant mice. In this study, the serum concentration
of interleukin (IL)-17 and the proportions of CD8þT cells and Th17 lymphocytes in the spleen were
signiﬁcantly higher in the susceptible group. Using genetic approaches, Block et al. [11] demonstrated
that gut microbiota regulates arthritis through follicular helper T (Tfh) cells, which are defective in
antibiotic-treated mice, but not Th17 cells. In particular, the authors investigated the contribution of
Th17 and Tfh cells in the induction of arthritis in a K/BxN autoimmune arthritis model that is
dependent on segmented ﬁlamentous bacteria for the induction of the autoimmune phenotype. The
authors particularly studied howmicrobiota modulates the differentiation of Th17 and Tfh cells. Using
genetic approaches, they demonstrated that IL-17 is dispensable for arthritis and that antibiotic
treatment inhibits disease in IL-17-deﬁcient animals; this suggests that the gut microbiota regulates
arthritis independent of Th17 cells. In contrast, conditional deletion of Bcl6 in T cells blocked Tfh cellPlease cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
j.berh.2016.10.003
Fig. 1. Dysbiosis in RA: Dysbiosis is present in RA patients and may modulate local and systemic immune responses such as the
induction of differentiation of T helper follicular cells. The role of dysbiosis in modulating other effector T cells remains to be
elucidated. Porphyromonas gingivalis (PG) can induce the local production of citrullinated protein. PG produces a unique bacterial
enzyme, P. gingivalis peptidyl-arginine deiminase (PPAD), which has the ability to convert arginine residues in proteins to citrulline.
Since that protein citrullination alters protein structure, PPAD may be involved in alteration of the host's signaling network and
immune evasion.
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antibiotic-treated mice. Taken together, these ﬁndings indicate that gut microbiota regulates arthritis
through Tfh but not Th17 cells (Fig. 1).
Data fromhuman studies aremoremixed. On the one hand, there ismuch evidence that supports the
association between RA and the intestinal microbiota; bacteria such as Mycoplasma fermentans [12],
Escherichia coli [13], and Proteus mirabilis [14] have been reported to initiate the disease. On the other
hand, it has been demonstrated that gastrointestinal and urogenital infections are associated with a
signiﬁcantly lowered risk of RA [15] and that patients with RA exhibit decreased gut microbial diversity
compared with controls [16]. In particular, it has been proved that expansion of rare taxa such as
Actinobacteria along with decrease in abundant taxa occur in patients with RA compared with controls
[16]. In this study, three genera, Collinsella, Eggerthella, and Faecalibacterium, were found to be associated
with RA; abundance of Collinsella was strongly correlated with the production of the proinﬂammatory
cytokine IL-17A [16]. The role of Collinsella in altering gut permeability and disease severity has been
conﬁrmed in experimental arthritis [16]. A more recent study evaluated human fecal Lactobacillus
community and its relationshipwith RA [17]. Samples obtained fromRApatients and healthy individuals
were analyzed and demonstrated that fecal microbiota of RA patients contained signiﬁcantly morePlease cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
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alterations in RA-associated gut and oral microbiomes were observed, which were partly relieved by
disease modifying anti-rheumatic drugs (DMARD) treatment [18]. To delineate the features of the RA-
associated gut microbiome, the authors performed a microbiome genome-wide association study
identifying 117,219 gene markers that were differentially enriched in RA patients and controls and
clustered these genes into metagenomic linkage groups (MLGs) on the basis of their correlated abun-
dance variation among samples. Different from that of the controls, the RA-enriched MLGs formed a
large cluster containing strains such as Clostridium asparagiforme, Gordonibacter pamelaeae, Eggerthella
lenta, and Lachnospiraceae bacterium and small clusters or single MLGs containing strains such as Biﬁ-
dobacterium dentium, Lactobacillus sp., and Ruminococcus lactaris. The RA gut was rich in gram-positive
bacteria and depleted of gram-negative bacteria, including some Proteobacteria and gram-negative
Firmicutes of the Veillonellaceae family. In accordance with the relative depletion of gram-negative
bacteria in RA, enrichment of the reductive acetyl-CoA pathway was present in individuals with RA
together with modules for converting acetate to methane. Conversely, modules involved in lipopoly-
saccharide biosynthesis, lipopolysaccharide transport, and secretion systems (type II, type IV, and type
VI) were more abundant in samples from healthy controls. Furthermore, several correlations with
prognostic or diagnostic factors were found. For instance, the abundance of RA-enrichedMLGs such as C.
asparagiforme and Bacteroides sp. was positively correlated with titers of immunoglobulin A (IgA) and
unclassiﬁed Lactobacillus sp. (most likely L. salivarius) was positively correlated with titers of the major
serum immunoglobulin, IgG. A positive correlation between Enterococcus faecalis and platelet count was
also detected. Bacteroides plebeius, Streptococcus australis, Veillonella sp., and Haemophilus parainﬂuenzae
were found to be negatively correlated with titers of the RA-speciﬁc autoantibodies ACPA and rheu-
matoid factor (RF). Furthermore, gut MLGs ﬁt the clinical indices, suggesting that the gut MLGs to some
extent could reﬂect the clinical variations among these subjects. Interestingly, molecular mimicry be-
tween RA-associated antigens such as Collagen XI and HLAeDRB1*0401 and gut microbial genes from
Clostridium, Eggerthella, Bacteroides, and Citrobacter was also observed. The above-mentioned studies
were performed on patients with established RA. However, early identiﬁcation of RA is a crucial step for
controlling the progression of the disease, and studying the bacterial composition in early stages of
disease may provide interesting information on its pathogenesis. Fecal microbiota in patients with early
RA and patients with Fibromyalgia has been recently studied and compared [19]. In this study, RA pa-
tients showed signiﬁcantly less biﬁdobacteria and bacteria from the Bacteroides-Porphyromonas-Pre-
votella group, Bacteroides fragilis subgroup, and Eubacterium rectale-Clostridium coccoides group.
Probiotics are microorganisms that can normalize gut microbiota and are potentially useful to
alleviate RA symptoms. Effects of probiotic supplementation on disease activity and inﬂammatory
cytokines in patients with RAwas recently studied by Vaghef-Mehrabany [20]. In this study, the disease
activity score was signiﬁcantly decreased by the probiotic supplementation. Tumor necrosis factor
(TNF)-a, IL-6, and IL-12were also signiﬁcantly decreased in the probiotic group, whereas serum level of
the regulatory cytokine IL-10 was increased by the supplementation.
Spondyloarthritis
Spondyloarthritis (SpA) is a generic term used for indicating inﬂammatory diseases that involve
both the joints and entheses (the sites where the ligaments and tendons attach to the bones) [21]. The
prototype of these diseases is AS. Other diseases include reactive arthritis, psoriatic arthritis (PsA), and
arthritis associated with inﬂammatory bowel disease. Involvement of the gastrointestinal tract in the
pathogenesis of SpA is strongly suggested because subclinical gut inﬂammation is present in up to 60%
of patients with SpA [22]. SpA-associated gut inﬂammation has been demonstrated to be an important
prognostic factor in SpA because it is associated with more extensive bone marrow edema of the
sacroiliac joints and a higher risk of progression to AS [23] and of developing Crohn's disease (CD) [24].
Histologic changes in the gut of SpA patients
Historically, gut inﬂammation in SpA patients has been classiﬁed into two categories: acute
inﬂammation, which resembles a self-limiting bacterial enterocolitis, and chronic inﬂammation, whichPlease cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
j.berh.2016.10.003
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nuclear cells that are sometimes aggregated in lymphoid follicles, resembling the ileo-colitis observed
in CD [22]. More recently, other relevant intestinal alterations have been demonstrated in AS gut: (i)
goblet cell hyperplasia and increasedmucin production [25], (ii) activation of paneth cells (PC) [26] and
hyperplasia of PC [27], particularly in PsA patients, (iii) detachment of epithelial cells from the basal
membrane [28], and (iv) occurrence of vasculitic lesions [28] that are mainly represented by intense
hemorrhagic extravasation of the lamina propria. Interestingly, similar tissue damages have been
described as a consequence of the response of epithelial cells to bacterial toxins [29]. The relative
contribution of the genetic factors involved in SpA pathogenesis in inﬂuencing these histologic changes
cannot be excluded and requires further study. The diagnosis of intestinal inﬂammation in SpA is
essentially made using endoscopy as reliable biomarkers are lacking. Recently, however, elevated
serum calprotectin and C-reactive protein (CRP) were demonstrated to be independently associated
with microscopic bowel inﬂammation [30]. During intestinal inﬂammation, fecal calprotectin is
elevated because of the migration of neutrophils to the inﬂamed intestinal mucosa [31]. In this study,
the authors suggested a screening approach where initially serum calprotectin, CRP, and, if necessary,
fecal calprotectin are assessed. The model using this scenario provided an area of 74.4% under the
Receiver Operating Characteristic (ROC) curve for the detection of bowel inﬂammation [30].
Immune alterations in the gut of SpA patients
In addition to the presence of histologic alterations, the intestine of SpA patients is characterized by
the abnormal activation of the innate and adaptive immune system and speciﬁc immunologic signa-
tures [32] (Fig. 2). Subclinical gut inﬂammation in patients with PsA seems to be characterized by the
overexpression of IL-9 and presence of fully developed Th9, Th17, and Th22 responses [27]. In
particular, in PsA, gut PC express a speciﬁc IL-9 receptor, and stimulation of isolated epithelial cells with
IL-9 up-regulates the expression of the antimicrobial peptide a-defensin 5 and cytokines, such as IL-23
and IL-9, which suggests the possibility of a functional autocrine loop that involves IL-9/IL-9R [27]. Th9
cells also increase in the peripheral blood and synovial tissues in PsA and express a4b7þ, indicating the
intestinal origin of these cells [27]. Conversely, in patients with AS, IL-23 over-expression dominates
and is mainly detected in the presence of PC without a clearly deﬁned Th17, Th1, and/or Th9 polari-
zation and Treg expansion [33,34].
The intestinal tract immune system is equipped with highly complex structures including the
tissue-speciﬁc organized lymphoid structures, the Peyer's patches (PPs), cryptopatches, and isolated
lymphoid follicles (ILFs) [35]. ILFs are induced postnatally by commensal microbiota and require the
presence of speciﬁc lymphoid structures called cryptopatches that contain lymphoid tissue inducer
(LTi) cells [36]. The recruitment and retention of lymphocytes into the cryptopatches requires IL-7
signaling on IL-7R-bearing LTi cells (a subtype of ILC3) [36]. This signal induces the expression of
lymphotoxin a1b2 (LT-a1b2) that in turn acts on resident lymphoid tissue organizer (LTo) cells [36].
Cryptopatches are virtually absent in the ileum of normal subjects [37], suggesting that bacterial
stimulation is necessary for them to develop in physiological conditions. Conversely, in the ileum of AS
patients, increased expression of IL-7, mainly in the presence of PC, is associated with the presence of
aggregates of LTi cells (CD3-c-kitþ/IL-7Rþ) that resemble murine cryptopatches [37] (Fig. 2). In
addition to their role in modulating the formation of cryptopatches, AS intestinal epithelial cells induce
the differentiation of type III innate lymphoid cells (ILCs) [37]. ILCs are heterogeneous populations of
lymphoid cells that do not display rearrangement of antigen receptors [38]. ILCs are distinguished into
three groups: IFN-g-producing ILC1 cells, T helper type 2 cytokine-producing ILC2 cells, and IL-17- and
IL-22-producing ILC3 cells that are essentially associated with the gastrointestinal mucosa [38]. In AS
patients, ILC3 are expanded in the gut and produce high levels of IL-17 and IL-22 [37]. It seems
reasonable that, under speciﬁc tissue-dependent factors, different subsets of ILC3s producing different
cytokines may act promoting different innate immune responses. In this scenario, ILC3s-producing IL-
22might be involved in tissue protective responses such as the induction of goblet cell hyperplasia and
increased mucin production, observed in AS gut. Conversely, IL-17- and IL-17/IL-22-producing cells
might be involved in eliciting pro-inﬂammatory actions. Interestingly, ILC3s are expanded also in the
peripheral blood, synovial ﬂuids, and bone marrow of AS patients. These extra-mucosal ILC3 expressPlease cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
j.berh.2016.10.003
Fig. 2. Subclinical gut inﬂammation in SpA patients is characterized by the presence of dysbiosis that seems to be responsible for the
loss of epithelial integrity and the systemic translocation of bacterial products. Circulating gut-derived bacterial products might
inﬂuence the function of circulating monocytes and antigen presenting cells. IL-23 immunologically characterizes AS-associated gut
inﬂammation and it seems to play an important role in SpA-associated gut inﬂammation by inducing the formation of cryptopatches
and the expansion of ILC3 that are able to re-circulate in extra-intestinal sites. Subclinical gut inﬂammation in PsA is immuno-
logically characterized by IL-9 over-expression and Th9 polarization. In PsA, gut-derived Th9 cells may re-circulate from the gut to
extraintestinal sites.
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highly expressed in the HEVs of the gut and in the inﬂamed bone marrow (BM) of AS [37], suggesting
that a recirculation of ILC3 between the gut and the BM occurs (Fig. 2). The importance of the a4b7/
MAdCAM1 axis in modulating tissue inﬂammation in AS, may be indirectly emphasized by the clinical
and radiographic efﬁcacy of a4b7 block with Natalizumab in AS patients [39]. In the light of these facts,
modulation of ILC3 trafﬁcking might be useful as a therapeutic strategy in AS. It is interesting to note
that anti-TNF therapy, a well established anti-inﬂammatory therapy in AS, results in systemic and
intestinal reduction of ILC3 and in strong reduction of intestinal expression of MAdCAM1 [37].
Mucosal-associated invariant T (MAIT) cellsda novel innate-like T-cell population, recognizing a
highly conserved antigen derived from the microbial riboﬂavin synthesis pathway [40]dhave been
recently implicated in the pathogenesis of AS. Gracey E et al. [41] recently demonstrated thatMAITcells
are reduced in frequency in the blood of patients with AS compared with HCs. AS patients, however,
have an elevated frequency of circulating and synovial IL-17Aþ MAIT cells, and IL-17 elevation in AS
MAIT cells seems to be dependent on priming with IL-7, but not IL-23 or antigen stimulation.Please cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
j.berh.2016.10.003
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Intestinal inﬂammation is strongly associated with the mucosal microbiota proﬁle of SpA patients
as demonstrated in the recent study from Tito et al. [42]. In this study, the bacterial community
composition of inﬂamed biopsies clustered separate from that of non-inﬂamed biopsies. Interestingly,
the authors demonstrated a positive correlation between the abundance of the genus Dialister and the
Ankylosing Spondylitis Disease Activity Score (ASDAS). This ﬁnding was further supported by the low
frequency of Dialister observed in non-inﬂamed SpA samples and healthy controls. A recent study
evaluated the community composition of gut microbiota in patients with PsA, patients with isolated
psoriasis of the skin, and healthy control subjects [43]. Samples were further assessed for the presence
and levels of fecal and serum secretory IgA (sIgA), proinﬂammatory proteins, and fatty acids. The gut
microbiota observed in patients with PsA and patients with skin psoriasis was characterized by the
reduced presence of several taxa. Samples from both patient groups showed a relative decrease in the
abundance of Coprococcus species, while samples from PsA patients were also characterized by a
signiﬁcant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. Supernatants of fecal
samples from PsA patients revealed an increase in sIgA levels and decrease in receptor activator of
nuclear factor kappa-B ligand (RANKL) levels. Analysis of fatty acids revealed low fecal quantities of
hexanoate and heptanoate in both patients with PsA and patients with psoriasis. A similar gut
microbiota proﬁle was present in patients with inﬂammatory bowel disease [43]. In children with
enthesitis-related arthritis (ERA) a different microbiome signature has been observed characterized by
(i) less Faecalibacterium prausnitzii and lachnospiraceae family, (ii) a statistically signiﬁcant increase in
Biﬁdobacterium, and (iii) an abundance of Akkermansia muciniphila [44]. Cluster analysis revealed the
presence of two clusters of ERA patients: in cluster one there were high levels of Bacteroides genus; in
cluster 2 similar levels of Bacteroides genus, but abundant A. muciniphila were observed, indicating
Bacteroides and A. muciniphila as associative agents in subsets of ERA patients. The presence of in-
testinal dysbiosis in AS is suggested by the evidence of over-expression of paneth cellsederived anti-
microbial peptides such as human a-defensin 5 (HD-5), phospholipase A2 (PLA2), and lysozyme in the
ileum of AS patients, with subclinical gut inﬂammation [26]. This alteration likely represents an
important early alteration of the mucosal innate immune component and intestinal host defense in AS.
The comparison of the fecal microﬂora of patients with AS and with that of the controls using mo-
lecular methods of analysis demonstrated a higher prevalence of sulfate-reducing bacteria in the feces
of the patients [45]. Interestingly, the concentration of serum antibodies reactive with whole cells of
Klebsiella pneumoniae or Bacteroides vulgatus was lower in the sera of patients compared with that of
controls, and the CD4þ lymphocyte proliferation index, after exposure to homologous Bacteroides cells,
was greater in AS than in controls [45]. These ﬁndings seem to indicate a possible loss of immunological
tolerance to autologous Bacteroides in AS.
Recently, Costello et al. [46] performed culture-independent microbial community proﬁling,
demonstrating differences in the gut microbiome of terminal ileum biopsy specimens between AS
patients and healthy controls. Ileal microbial communities of patients with AS differed signiﬁcantly
from that of healthy controls, being characterized by higher abundance of ﬁve bacteria families:
Lachnospiraceae, Veillonellaceae, Prevotellaceae, Porphyromonadaceae, and Bacteroidaceae. Altogether
these ﬁndings indicate the presence of different associative bacterial agents in SpA. In this regard,
further studies are required to speciﬁcally address the role of intestinal dysbiosis in the pathogenesis of
SpA and the inﬂuence of host genetics in changing intestinal microbial composition.
Despite a theoretical rationale for probiotic therapy, Jenks K et al., in a recent randomized controlled
trial, did not demonstrate any probiotic beneﬁt in SpA patients [47]. The primary outcome measure of
this study was 10% improvement in the Bath Ankylosing Spondylitis functional index (BASFI). Addi-
tional outcome measures were improvements in the Assessments in Ankylosing Spondylitis (ASAS)e
endorsed core domains: pain, spinal mobility, patient global, peripheral joint, and entheseal scores,
stiffness, C-reactive protein, and fatigue. Quality of life and bowel symptoms were quantiﬁed using the
Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) and Dudley Inﬂammatory Bowel
Symptom Questionnaire (DISQ). In this study, the probiotic combination administered did not
demonstrate signiﬁcant beneﬁt over the placebo in any of the core domains.Please cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
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There is increasing evidence that suggests that the gastrointestinal tract, and in particular, gut
dysbiosis could play a potential role also in the pathogenesis and progression of connective tissue
diseases (CTDs), such as systemic lupus erythematosus (SLE), Sj€ogren's syndrome (SS), and systemic
sclerosis (SSc).
Systemic lupus erythematosus
SLE is a chronic multisystem autoimmune disease that can potentially lead to serious organ
complications [48]. Changes in intestinal microbiome have been found both in lupus animal models
and in SLE patients, however the exact cause-effect relationship between alterations of the gut
bacterial composition and the development of the disease remains still to be elucidated. Two different
models of interaction between the gut microbiome and the immune system in SLE have been pro-
posed [49]. In the ﬁrst, it has been hypothesized that, in a pre-clinical stage of SLE, dysbiosis could
promote an aberrant mucosal immune response to self-antigens, and as a consequence, enhance a
local and systemic inﬂammatory state with hyperactive antibody production and disease manifes-
tations in predisposed subjects. Conversely, in the other model, dysbiosis could be not a cause, but an
epiphenomenon of the altered SLE-related immune reactions toward speciﬁc commensal bacterial
antigens disturbing intestinal homeostasis with subsequent breakdown of tolerance. Research con-
ducted on animal models has demonstrated both the presence of dysbiosis and immunoregulatory
functions of microbiome in lupus-prone mice. Zhang et al. [50] observed that female lupus-prone
(Mixed lymphocyte reaction) MRL/lpr mice display an increase in fecal Lachnospiraceae and a
decrease in Lactobacillaceae compared to age-matched healthy controls. In addition, a different
composition of gut microbiota was observed between the sexes, with an over-representation of
Lachnospiraceae in female mice, linked to the development of more severe disease. Remarkably, lupus
manifestations were improved with oral retinoid acid treatment concurrently with the Lactobacilli
restoration. Analyzing immunologic differences in the gut of female lupus-prone SNF1 mice, which
develop a more severe form of nephritis than male mice, Gaudreau et al. [51] demonstrated that
female SNF1 mice have more plasma cells and a4b7 T cells in the Peyer's patches and much higher
pro-inﬂammatory cytokines as IL-6, IL-9, IL-17, IL-22, IFN-a, and IFN-b in distal ileum than their male
counterparts. Although the microbiome composition was not analyzed in this study, it has been
hypothesized that the observed mucosal immune differences between the sexes may be the
expression of an underlying altered gut bacterial ﬂora. In a recent work, Johnson et al. showed that
dietary manipulation may inﬂuence gut microbiota composition, and consequently, inﬂammation
and disease progression in lupus SNF1 mice [52]. The authors demonstrated that, compared to SNF1
mice receiving neutral (pH 7.0e7.2) water (NW), mice receiving acidiﬁed (pH 3.0e3.2) water (AW)
displayed a delay in nephritis onset, less anti-dsDNA and anti-nucleohistone production, and a
reduction in kidney inﬂammatory inﬁltrate as well as a reduction in small intestine expression of
Th17-related cytokines such as IL-17, IL-21, and IL-23. Gut microbiome analysis revealed signiﬁcant
differences between AW and NW mice with the observation of a promoted growth of Firmicutes
bacteria in AW mice, as also previously demonstrated in humans. Moreover, the transfer of gut
microbiota by oral gavage from AW to NWmice, interestingly, was able to suppress lupus progression
in NW mice. This evidence supports the determining role of intestinal microbiome in promoting
development and activity ﬂare of lupus in SNF1 mice. In SLE patients, gut dysbiosis was ﬁrst observed
many years ago by Apperloo-Renkema et al. [53], who demonstrated the presence of different bio-
types of Enterobacteriaceae in active SLE than inactive patients and healthy subjects. Recently, Hevia
et al. [54] found a lower Firmicutes/Bacteroidetes ratio in SLE patients than in healthy subjects
(median ratio 1.97 vs. 4.86; p < 0.002) and demonstrated that microbiota isolated from SLE patient
stool samples was able to promote Th17 differentiation from naïve CD4-positive lymphocytes more
than healthy control microbiota. Interestingly, when microbiota was enriched with Treg-inducer
bacteria, such as some Clostridia strains, the Th17/Th1 balance was signiﬁcantly reduced, thus sup-
porting a possible therapeutic approach with probiotics in restoring the imbalance between Th17 and
Treg-Th1 present in SLE. Moreover, analyses of fecal microbiota revealed that Firmicutes bacteria,Please cite this article in press as: Ciccia F, et al., The role of the gastrointestinal tract in the pathogenesis
of rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/
j.berh.2016.10.003
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that was found slightly reduced in patients, and negatively correlated with IL-17epositive pop-
ulations in healthy controls [55]. Finally, the authors found a positive correlation between the Syn-
ergistetes and the Firmicutes/Bacteroidetes ratio in healthy controls. Synergistetes tended to be
reduced when anti-dsDNA titers and IL-6 serum levels were increased and correlated positively with
protective natural IgM antibodies against phosphorylcholine [55]. Collectively these ﬁndings show
that both lymphocytic polarizations and natural protective immune defenses could be inﬂuenced by
the gut microbiota composition in SLE patients. Metabolomic studies [56] were also performed in
order to investigate the presence of potential disease-related alterations of fecal metabolites in SLE
patients. A deﬁciency in amino acid metabolism and in metabolites associated with pyrimidine and
purine was observed in the stool of patients than healthy controls, but with differences too limited to
establish what could be its real pathophysiologic implication.
Sjogren's syndrome
Sjogren's syndrome (SS) is a systemic chronic inﬂammatory disorder characterized by lymphocytic
inﬁltrates in exocrine organs [57]. The majority of studies about dysbiosis in SS have evaluated the
implications of hyposalivation on the oral bacterial ﬂora alterations [58,59]. According to themolecular
mimicry model, SS would be the result of a still unknown complex network of interactions between
genetic and environmental factors, likely infectious-related antigens, that could trigger an abnormal
self-perpetuating pro-inﬂammatory state, leading to autoimmunity and lymphoproliferation [57].
While the potential role of viruses in SS pathogenesis has been widely explored, only one study that
focused on a possible implication of bacteria in SS development is currently available. To test this
hypothesis, Szymula et al. [60] created Ro62/SSA reactive T cell hybridomas from HLA-DR3 transgenic
mice for the susceptibility for SS and SLE, and evaluated their reactivity against oral, gut, and skin
bacteriaederived peptides. The authors found that several antigens from normal commensal micro-
biota were able to activate Ro62/SSA T cell hybridomas. The most potent stimulator was identiﬁed in
the von Willebrand factor type A domain protein (vWFA), mainly expressed by Bacteroides intestinalis
in the gut and Capnocytophaga ochracea in the oral mucosa. These ﬁndings suggest that the activation
of T cell in SS could be primed at the mucosal level by exposure to mimicry antigens from normal
commensal bacterial ﬂora, contributing to the initiation of autoimmune responses in SS.
Systemic sclerosis
Research studies examining the role of dysbiosis in Systemic sclerosis (SSc) are lacking. A recent study
[61] was undertaken to investigate the hypothesis that SSc could be associated with altered gut bacterial
composition in the colon tract, and mainly that gastrointestinal (GI) symptoms in SSc patients could
mirror some underlying microbiome alterations. The authors demonstrated that there were signiﬁcant
differences in the microbial communities found in mucosal lavage samples from the cecum and sigmoid
tracts of SSc patients when comparedwith healthy controls. SSc patients showed signiﬁcantly decreased
levels of commensal ﬂora, such as Faecalibacterium and Clostridium, and increased levels of Fusobacte-
rium and g-Proteobacteria, compared to healthy subjects. Biﬁdobacterium and Lactobacillus were also
increased inpatientswith SSc.Moreover, SSc patientswith gastrointestinal symptoms had an abundance
of Fusobacterium and a decrease in the levels of Bacteroides fragilis compared to patients without or
with mild symptoms. Thus, this study demonstrated a particular bacterial signature in SSc patients that
may perpetuate immunologic alterations and contribute to the clinical manifestations in SSc.
Summary
Overall, available evidence conﬁrms the existence of a strong association between intestinal dys-
biosis and RA and connective tissue diseases. Further studies are however needed to establish the
clinical relevance of intestinal inﬂammation in these patients and the exact impact of gut microbiota in
inﬂuencing the initiation of autoimmune response and themodulation of the activity in these diseases.
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and the immune system. The identiﬁcation of a speciﬁc “dysbiotic signature” for each disease could
allow the development of a complimentary therapeutic approach based on treatments targeted to
restore a favorable microbiota balance.Practice points
 The gastrointestinal tract plays a key role in the pathogenesis of SpA by modulating innate
and adaptive immune responses.
 Dysbiosis seems to be relevant in modulating intestinal inflammation in SpA.
 Dysbiosis occurs in patients with CTD and RA.
Research agenda
 We need to better study the role of gastrointestinal tract in the pathogenesis of RA and CTD.
In particular, we have to clarify whether a “subclinical gut inflammation” occurs in these
patients and whether it may modulate local and systemic responses.Disclosures
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